Aquestive Therapeutics Inc. (AQST), which is developing the first and only non-device based, oral epinephrine product candidate for anaphylaxis, has a clinical trial catalyst to watch this quarter.
Anaphylaxis is a severe and rapidly occurring systemic hypersensitivity reaction that can be life-threatening. Primary triggers for reactions leading to anaphylaxis often involve medications, specific foods (such as peanuts), and insect sting venom.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com